Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
27 hedge funds and large institutions have $5.26M invested in Carisma Therapeutics in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 8 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 2
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
9% more capital invested
Capital invested by funds: $4.82M → $5.26M (+$448K)
0% more funds holding
Funds holding: 27 → 27 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 0.52% → 0.48% (-0.04%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $37K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$927K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$196K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$135K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$114K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$61.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$343K |
| 2 |
SIM
Spark Investment Management
New York
|
-$268K |
| 3 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$97.9K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$56K |
| 5 |
AL
Airain Ltd
St. Peter Port,
Guernsey
|
-$48K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IWM
26
IHT Wealth Management
Chicago,
Illinois
| $1K | +$1.04K | +25 | New |
|
27
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $1K | +$1.46K | +35 | New |
|
|
OAM
28
Oxford Asset Management
Oxford,
United Kingdom
| – | -$343K | -8,981 | Closed |
|
|
SIM
29
Spark Investment Management
New York
| – | -$268K | -7,025 | Closed |
|
|
VKH
30
Virtu KCG Holdings
New York
| – | -$56K | -1,474 | Closed |
|
|
AL
31
Airain Ltd
St. Peter Port,
Guernsey
| – | -$48K | -1,258 | Closed |
|
32
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$32.5K | -779 | Closed |
|
|
CS
33
Credit Suisse
Zurich,
Switzerland
| – | -$28K | -743 | Closed |
|
CARM Hedge Fund Activity: Q1 2017 in Review
27 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2017, worth a combined $5.26M — up 9.3% from $4.82M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CARM positions and 8 closed out — a net gain of 2 holders — while 10 added to existing stakes and 2 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $927K. The largest seller was Oxford Asset Management, exiting entirely with an estimated $343K sold.
- 27 institutional investors held Carisma Therapeutics (CARM) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $5.26M of Carisma Therapeutics stock for Q1 2017, up 9.3% quarter-over-quarter.
- 10 funds opened new Carisma Therapeutics positions in Q1 2017 and 8 closed out, a net change of +2 holders.
- The largest Carisma Therapeutics buyer in Q1 2017 was BlackRock, an estimated $927K added.
- The largest Carisma Therapeutics seller in Q1 2017 was Oxford Asset Management, an estimated $343K sold.
Based on aggregated 13F filings for Q1 2017.